IVERIC bio (ISEE) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results
May 4, 2022 6:32 AM EDT- Zimura® GATHER2 Topline Data Expected in the Third Quarter of this Year-
- GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90%
- U.S. Patent Covering Methods of Treating GA with Zimura Granted by USPTO
- Conference Call and Webcast Today, May 4, 2022, at 8:00 a.m. ET
PARSIPPANY, N.J.--(BUSINESS... More
